about
Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies.Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil.Psychometric validation of the Confidence in Performing Sexual Intercourse Questionnaire and Difficulty in Performing Sexual Intercourse Questionnaire.Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol.Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia.The role of initial success rates and other factors in determining reliability of outcomes of phosphodiesterase inhibitor therapy for erectile dysfunction: a pooled analysis of 17 placebo-controlled trials of tadalafil for use as needed.Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment.Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: validation of an anchor-based treatment responder classification.Estimated risk of invasive breast cancer in postmenopausal women with and without family history of the diseaseTreatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study
P50
Q30872617-B7348ABA-7E61-487D-BFCE-3B86A565641AQ42609456-4C9631D0-8611-42CA-9408-25D7C4D36635Q43652712-2E440723-7A4C-4BAB-AA6F-C4E8FD8F850CQ46006318-FA3B47C7-47FD-49AD-AEEF-7C9AD8B95500Q46575882-1144850D-27EB-49FE-9D46-B90A251462B3Q47244277-41098E2F-2D7F-4234-94F4-B0509E4AF162Q47898576-6F821F9E-E721-44A2-BA2F-A1217BF16FD2Q53101620-4A355FF5-E9E0-4457-9BFE-BFBEFD058313Q82998834-E8AD128C-9C2E-4A4E-88FA-B9C5BB2F8A02Q87418135-34A92A11-6DA5-43C7-B429-28FF119DB2B5
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Angelina Sontag
@ast
Angelina Sontag
@en
Angelina Sontag
@es
Angelina Sontag
@nl
type
label
Angelina Sontag
@ast
Angelina Sontag
@en
Angelina Sontag
@es
Angelina Sontag
@nl
prefLabel
Angelina Sontag
@ast
Angelina Sontag
@en
Angelina Sontag
@es
Angelina Sontag
@nl
P106
P21
P31
P496
0000-0003-4012-4537